Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis

Company Overview

Scinai Immunotherapeutics Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company is developing treatments designed to target disease-related immune pathways while potentially providing localized delivery and reduced systemic exposure.

Scinai’s development platform is based on NanoAbs, or nanobodies, which are small antibody-derived molecules intended to bind selectively to therapeutic targets. Its lead program is an anti-IL-17 NanoAb candidate being developed for topical treatment of psoriasis and potentially other inflammatory conditions. The company is also evaluating additional applications for its platform across immune-mediated diseases.

Scinai serves the biopharmaceutical market through research and development of its proprietary therapeutic candidates and technology platform. The company is headquartered in Israel and is conducting its work as a development-stage biotechnology business; product candidates remain subject to clinical testing and regulatory review before they can be marketed.

Key Stats

• Today's Range: $1.06 to $1.23
• 50-Day Range: $1.13 to $3.22
• 52-Week Range: $1.06 to $15.80
• Volume: 89,325 shs
• Average Volume: 3.26 million shs
• Market Capitalization: $855.47 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Scinai Immunotherapeutics Stock Analysis - MarketRank™

Scinai Immunotherapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Scinai Immunotherapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Scinai Immunotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scinai Immunotherapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scinai Immunotherapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

163.64% of the float of Scinai Immunotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Scinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scinai Immunotherapeutics has recently increased by 5,382.31%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scinai Immunotherapeutics does not currently pay a dividend.

Dividend Growth

Scinai Immunotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.90% of the stock of Scinai Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2025
• Today: 10/08/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SCNI
• Previous Symbol: NASDAQ:SCNI
• CIK: 1611747
• Web: www.scinai.com
• Phone: 972-8-930-2529
• Fax: 972-8930-2531
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.56
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $1.49 million
• Price / Sales: 0.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.77 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 707,000
• Free Float: 276,000
• Market Cap: $855.47 thousand
• Optionable: Not Optionable
• Beta: 2.13